Ultragenyx Pharmaceutical Inc. (RARE)

43,85 -0,43 (-0,97 %) À la clôture : 04:00PM EDT

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1 276

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Emil D. Kakkis M.D., Ph.D.	Founder, President, CEO & Director	1,37M	S.O.	1960
Mr. John Richard Pinion II	Chief Quality Operations Officer & Executive VP of Translational Sciences	806,19k	S.O.	1966
Mr. Erik Harris	Executive VP & Chief Commercial Officer	848,24k	S.O.	1971
Mr. Howard Horn	Executive VP of Corporate Strategy & CFO	S.O.	S.O.	1978
Mr. Theodore A. Huizenga	Senior VP, Corporate Controller & Principal Accounting Officer	S.O.	S.O.	1971
Ms. Danielle Keatley	Senior Director of Investor Relations & Corporate Communications	S.O.	S.O.	S.O.
Ms. Karah Herdman Parschauer J.D.	Chief Legal Officer & Executive VP of Corporate Affairs	595,01k	122k	1978
Mr. Ernie W. Meyer	Chief Human Resources Officer & Executive VP	S.O.	S.O.	1965
Mr. Thomas R. Kassberg	Chief Business Officer & Executive VP	714,84k	S.O.	1960
Mr. Vimal Srivastava	Senior Vice President of Business Development & Alliance Management	S.O.	S.O.	1965

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Ultragenyx Pharmaceutical Inc. en date du 1 avril 2024 est 4. Les scores principaux sont Audit : 2; Société : 1; Droits des actionnaires : 7; Compensation : 5.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.